CYCLOPHOSPHAMIDE MONOHYDRATE, BORTEZOMIB, ISATUXIMAB, LENALIDOMIDE, DEXAMETHASONE, DEXAMETHASONE
EAE116
Phase 2 small_molecule active
Quick answer
CYCLOPHOSPHAMIDE MONOHYDRATE, BORTEZOMIB, ISATUXIMAB, LENALIDOMIDE, DEXAMETHASONE, DEXAMETHASONE for Newly diagnosed patients with multiple myeloma and severe renal impairment is a Phase 2 program (small_molecule) at Ology Bioservices Ireland LTD with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Ology Bioservices Ireland LTD
- Indication
- Newly diagnosed patients with multiple myeloma and severe renal impairment
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active